secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126322
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial
--------------------------------------------------------------------------------

- Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.
- Cash and marketable securities $178.8M at Dec 31, 2025, up from $97.5M.
- Closed $115M public offering of common stock and pre-funded warrants in Nov 2025.
- Initiated global adaptive Phase 3 IMPROVE-PAH study for IKT-001 in PAH; Part A (140 pts, PVR) then Part B (346 pts, 6MWD).
- Regulatory submissions in >20 countries; FAST-EU acceptance for accelerated trial approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/0001193125-26-126322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/d119328d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer